IP Library Granted Patent US 7,750,041
Granted Patent B2
US 7,750,041 · App. 10/472,844 · Granted Jul 6, 2010

Preparation for the prophylaxis of restenosis

Assignee: Bayer Schering Pharma Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,750,041
App. No.
10/472,844
Granted
Jul 6, 2010
Kind
B2
Abstract

The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water ≧0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.

Claims (11)

1. An angiography catheter comprising a coating comprising a dried preparation comprising a mixture of (a) paclitaxel and (b) iopromide, wherein said angiography catheter is an inflatable balloon catheter, the balloon of which has a surface coated only with said coating.

2. The balloon catheter according to claim 1 , wherein (a) and (b) are coated onto the catheter using ethanol as solvent.

3. The catheter of claim 1 , wherein the agent is not enclosed by a solubility mediator in externally hydrophilic micelles.

4. The catheter of claim 1 , wherein said preparation additionally contains a coagulation inhibitor and/or a platelet aggregation inhibitor and/or an enzyme inhibitor and/or a calcium chelator.

5. The catheter of claim 1 , wherein at least 10% of the paclitaxel binds reversibly or irreversibly to tissue after contact between said coating and said tissue.

6. The catheter of claim 1 , wherein a component of the preparation shows a specific affinity towards vessel walls.

7. The catheter of claim 1 , wherein the preparation contains a non-micelle forming solubility mediator.

8. The catheter of claim 1 for restenosis prevention upon contact of said coating with tissue.

9. A catheter of claim 1 , wherein said paclitaxel is dissolved in said iopromide during preparation of said mixture.

10. A catheter of claim 1 wherein said balloon optionally carries a cardiovascular stent which is also optionally coated.

11. A catheter of claim 1 wherein said coating is preparable by immersing said balloon in said mixture prior to its drying.

Assignments (4)
CHANGE OF NAME Recorded Jun 12, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030596/0598 →
CHANGE OF NAME Recorded Feb 17, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 027728/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2009
From: SPECK, ULRICH
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023722/0691 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2004
From: SCHELLER, BRUNO
To: ULRICH SPECK
Reel/Frame 015150/0336 →
Priority Claims (1)
DE 101 15 740 · Mar 26, 2001 · national
Continuity (2)
Related Publication 20050101522A1 · May 12, 2005
Related Publication 20050250672A9 · Nov 10, 2005